Age and early graft function relate with risk-benefit ratio of allogenic islet transplantation under Anti-thymocyte globulin - Mycophenolate mofetil - Tacrolimus immune suppression by Lee, Da Hae et al.
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
Transplantation Publish Ahead of Print
DOI: 10.1097/TP.0000000000001543
  
 
Age and early graft function relate with risk-benefit ratio of allogenic islet 
transplantation under Anti-thymocyte globulin – Mycophenolate mofetil  – Tacrolimus 
immune suppression 
 
Da Hae Lee
1,2
, Bart Keymeulen
2
, Robert Hilbrands²,  Zhidong Ling², Ursule Van de Velde², Daniel Jacobs-
Tulleneers-Thevissen
2
, Geert Maleux
3
, Bruno Lapauw
4
, Laurent Crenier
5
, Christophe De Block
6
,  
Chantal Mathieu
1
, Daniel Pipeleers
2
, Pieter Gillard
1,2 
 
1 
Department of clinical and experimental medicine, Katholieke Universiteit Leuven and University 
Hospitals Leuven 
2 
University Hospital and
 
Diabetes Research Center, Vrije Universiteit Brussel-VUB  
3 
Department of Interventional Radiology, University Hospitals Leuven, KUL
 
4 
Department of Endocrinology, Gent University Hospital
  
5
 Department of Endocrinology, Université Libre de Bruxelles–Hôpital Erasme 
6 
Department of Diabetology, University Hospital Antwerp-UA 
 
Corresponding author 
Pieter Gillard 
Address:  
Department of Endocrinology Herestraat 49, 3000 Leuven and  
Diabetes Research Center, Laarbeeklaan 103, 1090 Brussel 
Telephone number: +32-16346994 
Fax: +32-16346989 
Email: Pieter.gillard@uzleuven.be 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
  
 
Clinical Trial registration: ClinicalTrials.gov NCT00623610 and NCT00798785 
Contribution statement: 
D.L., B.K. and P.G. contributed to the study design, literature search, data collection, data analysis and 
interpretation and writing of the manuscript. R.H., U.V.d.V., and Z.L. researched data and reviewed the 
manuscript. D.J.T.T., G.M.  contributed to data research and reviewing of the manuscript. B.L., C.D.B., 
L.C. contributed to the patient recruitment, data research, and reviewing of the manuscript. C.M. researched 
the data and reviewed the manuscript. D.P. contributed to the discussion and editing of the manuscript. P.G. 
and B.K. are the guarantors of this work and, as such, had full access to all the data in the study and take 
responsibility for the integrity of the data and the accuracy of the data analysis. 
 
Disclosures: 
The authors declare no conflicts of interest. 
 
Funding: 
This study was supported by the Juvenile Diabetes Research Foundation (JDRF grants 4-2001-434, 4-2005-
1327), the Research Foundation Flanders (FWO Vlaanderen projects WO 040.04. G.0311.07-10. 
G.0800.09N, senior clinical research fellowship for BK), the W. Gepts Fund of University Hospitals 
Brussels (project 71046) and the Vrije Universiteit Brussel (project OZR1915). P.G. is funded by the 
Clinical Research Foundation of the University Hospitals Leuven, Katholieke Universiteit Leuven. B.K. is 
senior clinical investigator of the Research Foundation Flanders (Fonds Wetenschappelijk Onderzoek-
Vlaanderen). 
 
Abbreviations 
AE, Adverse events 
ATG, Anti-thymocyte globulin 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
  
CMV, Cytomegalovirus 
CVfg, Coefficient of variation of fasting glycemia 
IQR, Interquartile range 
IS, Immune suppression 
MMF, Mycophenolate mofetil 
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Abstract 
 
Background: Induction therapy with a T cell depleting agent followed by mycophenolate mofetil (MMF) 
and tacrolimus (Tac) is presently the most frequently used immune suppression (IS) regimen in islet 
transplantation. This study assesses its safety and tolerability in nonuremic type 1 diabetic recipients.   
Methods: Fifty-one patients (ages between 29-63 years) with high glycemic variability and problematic 
hypoglycemia received intraportal islet grafts under anti-thymocyte globulin (ATG)-MMF-Tac protocol. 
They were followed over 48 months for function of the implant and adverse events. 
Results: Severe hypoglycemia and diabetic ketoacidosis were absent in patients with functioning graft. 
Immune suppressive therapy was maintained for 48 months in 29 recipients with sustained function (group 
A) while in 16 patients stopped earlier due to graft failure (group B) and in 6 for other reasons. Group A was 
significantly older at the time of implantation and achieved higher graft function at posttransplant (PT) 
month 6 under similar dose of IS. Prevalence of IS-related side effects was similar in group A and B, 
occurring predominantly during the first year PT. IS-related serious adverse events (SAE) were reported in 
47% of patients, with 4 presenting with CMV infection and 4 (age 42 to 59 years) diagnosed with cancer. 
Except in 1 patient with cancer, all SAE resolved after appropriate treatment.   
Conclusions:  These risk/benefit data serve as a basis for clinical decision-making before entering an 
intraportal islet transplantation protocol. A longer benefit is observed in recipients of higher age (≥40 yrs), 
but it is not associated with more side effects and SAE. 
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Introduction 
For type 1 diabetic patients with problematic hypoglycemia, islet transplantation represents a possibility of 
therapy (1-3).  However, the risk benefit ratio needs to be determined. This is not easy in view of the 
heterogeneity of the recipients and in the transplant protocols.  Single center protocols usually have 
standardized follow-up of graft function, metabolic control and safety outcome measurements (2,4-7). 
Because of the limited number of patients per center, analysis is often conducted in a combination of 
preuremic and kidney transplant recipients and of patients under different immunosuppressive regimens (8). 
In Belgium, a collaborative Islet Transplant Network was formed, with islets being isolated in the central 
isolation facilities of the Diabetes Research Center of the Vrije Universiteit Brussel (VUB) and 
transplantations being performed by a collaborative team in 2 Belgian academic centers (6). The present 
study examines risk-benefit ratio of well-characterized human islet cell grafts in nonuremic type 1 diabetic 
patients receiving immune suppressive therapy that consists of anti-thymocyte globulin (ATG) as induction 
and mycophenolate mofetil (MMF) plus tacrolimus (Tac) as maintenance. This combination of T-cell 
depletion and MMF-Tac is currently the most frequently used regimen in islet transplantation (9) and has 
been used in our program for more than 15 years (10). 
 
Materials and Methods 
 
Graft Recipients 
Data were collected from a total of 51 islet beta cell recipients with type 1 diabetes mellitus complicated by 
hypoglycemia unawareness, transplanted between December 2001 to March 2011. Baseline patient 
characteristics are shown in Table 1. The recipients were included according to the following criteria: 1. 
Nonsmokers ages between 18 to 65 years; 2. C-peptide negativity defined as plasma C-peptide < 0.09 ng/ml 
at glycaemia of 120 – 200 mg/dL; 3. Signs of chronic diabetic complications (microalbuminuria despite 
optimal dose of angiotensin-converting enzyme inhibitor, retinopathy, or hypoglycemic unawareness); 4. 
Large within-person between-day variation in fasting self-monitored plasma glucose (defined by coefficient 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
  
of variation fasting glycaemia [CVfg] ≥25% and HbA1c ≥7% or 53 mmol/mol despite 4 daily subcutaneous 
insulin injections or pump therapy.  Female patients of childbearing potential were excluded. Ethics 
Committee of the Belgian Diabetes Registry (BDR) and the participating university hospitals approved the 
protocol. This study was performed according to the Declaration of Helsinki and institution review board 
approval was obtained (institutional review board protocol BK/3 and BK/136; clinicaltrials.gov 
NCT00623610 and NCT00798785). A written informed consent was obtained from every patient.  
 
Preparation of islet beta cell grafts and transplantation 
Isolation and preparation of islet beta cell allografts was as described previously (6). The technique to access 
the portal vein depended on the expertise of the site were patients were transplanted, either by laparoscopy 
(University Hospital Brussels (11)) or by percutaneous fluoroscopic-guided trans-hepatic injection 
(University Hospital Leuven (12)). In total 91 grafts were transplanted of which 41 grafts (n=22 patients) 
were transplanted by laparoscopic and 50 grafts (n=29 patients) by percutaneous cannulation of the portal 
vein. Twelve patients received 1 implant, 38 patients 2 implants within 3 months (IQR 2.4-3.5 months) after 
the first implantation and 1 patient received 3 implants (at 2.5 and 5 months posttransplantation). Based on a 
possible beneficial effect of intravenous heparin infusion peritransplant as reported by Koh et al (13), 
heparin was administered in 3 patients undergoing laparoscopic implantation at 70 U/kg using continuous 
infusion of heparin containing saline (10U/ml) at 500 U/h (50ml/h) up to 24 hours post-transplantation (PT). 
After intra-abdominal bleeding in 2 of the 3 cases, heparin administration was removed from the protocol. 
Doppler ultrasonography of the portal vein and liver was performed within 24 hours PT to rule out bleeding 
and thrombosis. 
 
Immune suppression and monitoring 
The immune suppression regimen consisted of induction therapy with anti-thymocyte globulin (ATG-
Fresenius®, Fresenius, HemoCare, Redmond,WA) and maintenance therapy with mycophenolate mofetil 
(MMF, Cellcept®, Roche, Basel, Switzerland, n=46) or mycophenolic acid (Myfortic®, Novartis, Basel, 
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Switzerland, n=5) and tacrolimus (Prograf(t)®, Astellas Pharma Europe, Staines, UK).  First dose of ATG 
was given at day 4 (n = 21) or day 1 (n = 30) before the first implantation (9 mg/kg) and continued at 3 
mg/kg for 6 days if T-lymphocyte count was above 50 /mm³.  No additional ATG was administered at the 
second or third implantation. MMF (2g/day) or mycophenolic acid (1440 g/day) was started together with 
the first ATG injection and maintained at this dose, unless clinically necessary.  All 5 patients who were 
started with mycophenolic acid were switched over to MMF within the first year after transplantation, 
according to availability. Patients received Tac from day 2 (n=33) or day 5 (n=18) at a dose to achieve 
serum trough levels of 8-10 ng/ml first 24 months and 6-8 ng/ml thereafter. Two hours before the first ATG 
administration and before each beta cell graft, 500 mg methylprednisolone was given intravenously. 
 
Anti-infectious prophylaxis consisted of valganciclovir (Valcyte® 900 mg qd, Roche, Basel, Switzerland) 
and sulfamethoxazole/trimethoprim (Bactrim Forte® 800mg/160mg qd, Roche, Basel, Switzerland) during 
100 days after each implantation. 
 
Assessment of side effects and adverse events 
Outpatient follow up was performed weekly until PT week 6, and every 2 weeks between PT week 6 and 12 
and monthly thereafter. At each visit, a questionnaire was completed with a listing of possible adverse 
events and side effects, followed by a physical examination. Blood work was done for hematology, kidney 
and liver function, metabolic parameters, tacrolimus trough levels (Tacrolimus II, IMx Abbott; Abbott 
Laboratories, Wiesbaden, Germany) and cytomegalovirus polymerase chain reaction (Amplicor CMV-test; 
Roche Diagnostics). Adverse events (AE) were assessed and recorded following the Common Terminology 
Criteria for Adverse Events v3.0 (CTCAE), as recorded in the Clinical Islet Consortium (14), with the 
grading scale of 1, mild; 2, moderate; 3, severe; 4, life-threatening; and 5, death. Serious adverse events 
(SAE) were defined as fatal, life threatening, causing disability, causing or prolonging hospitalization, 
occurrence of malignancy or congenital anomaly, and requiring intervention to prevent permanent 
impairment or damage (15). The relationship between each adverse events and transplant protocol was 
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categorized by causality; definitely related, probably related, possibly related, probably not related, not 
related, and unknown.  Events reported from grade 2 to 5 were included in our analysis.  
 
Assessment of metabolic control and acute diabetic complications 
Plasma C-peptide, glycaemia, and HbA1c concentrations were measured in the central laboratory of the 
Belgian Diabetes Registry (6). All patients performed 4- to 7-point glycaemia profiles of home blood 
glucose monitoring.  Coefficient of variation of fasting glycaemia (CVfg) was calculated using the 
glycaemia measured from home blood glucose monitoring defined as the ratio of the standard deviation (δ) 
to the mean (µ): CVfg= δ/ µ.  Insulin dose-adjusted A1c (%) was calculated using HbA1c (%) + [4 x insulin 
dose (U/kg/day)](16). 
 
Graft failure was defined as consecutive random plasma C-peptide <0.2 ng/mL measured at glycaemia of 
120-220 mg/dL.  Hypoglycemic events were defined as blood glucose levels < 70 mg/dL and were assessed 
by records of home blood glucose self-monitoring. Severe hypoglycemia was defined as an event requiring 
assistance of a third party to actively administer carbohydrate, glucagon, or other resuscitative actions that 
may be associated with sufficient neuroglycopenia to induce seizure or coma. 
 
Diabetic ketoacidosis was defined as hyperglycemia (blood glucose >200 mg/dL) with metabolic acidosis 
(venous pH <7.3 or plasma bicarbonate < 15 mmol/L) and the presence of ketones in blood or urine.  This 
was documented with the use of patient reports and hospitalization records. 
 
Implant function and metabolic control data were compared between 2 patient groups, those who remained 
under IS until 48 months (Group A) and those who stopped IS during the follow-up due to graft failure 
(Group B). 
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Statistical methods 
Data collected were for intention-to-treat analysis.  All values are expressed as median and interquartile 
range (IQR) or mean ± standard deviation when indicated. For the comparison of the baseline patient 
characteristics, Pearson’s Chi-squared test was used for categorical data and Kruskal-Wallis for continuous 
data in 3 different patient groups.  To assess the difference between different time points during the follow 
up, Fisher’s exact test was used for categorical data and Mann-Whitney U test was used for continuous data.  
All analysis was performed using SPSS (version 22.0) and the graphics were computed by using Graph Pad 
Prism (version 5.0). All reported p-values are 2-sided and p<0.05 was considered statistically significant.  
 
Results 
 
Baseline patient characteristics of patients with continued and discontinued immune suppressive therapy 
Of the 51 patients, 29 continued IS for 48 months (Figure 1). The treatment was stopped earlier in 22 
patients (median duration 18 months (IQR 13-34)), in 16 because of a failing graft and in 6 for another 
reason in presence of a functioning graft. The latter group consisted of 2 patients diagnosed with cancer 
(malignant melanoma at month 13 PT; gastric adenocarcinoma with hepatic metastasis at month 27 PT), 1 
suffering from therapy-resistant cytomegalovirus infection between month 6 and 13 PT, 1 who died at age 
61 as a consequence of acute cerebral hemorrhage at month 4 PT and 2 who were disappointed that insulin-
independence was not achieved (month 7 and 10 PT). 
 
All 51 patients exhibited high pretransplant glycemic variability above 25% (Table 1). The majority had 
microvascular complications, with clinical macroangiopathy in 20 patients. 
 
There were no differences in gender, body weight or BMI in the recipients who continued or discontinued 
IS. Patients with graft failure were significantly younger (p=0.001) and exhibited worse glycemic control at 
time of transplantation, shown as corrected insulin dose (higher insulin dose-adjusted A1c (16)) (p=0.01).  
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Serious adverse events 
Of the 51 patients, 24 (47%) experienced SAE (Table 2). Three cardiovascular SAE were considered not to 
be study related.  
SAE related to the implant procedure were uncommon; they occurred in 3 out of 91 implant procedures 
(3%): 1 percutaneous implant caused severe thoracic pain associated with pleuro-peritoneal irritation at the 
site of puncture (Table 2).  No significant hemorrhage (defined as a drop in hemoglobin of more than 2 g/dl, 
or the need for transfusion or surgery) was seen after percutaneous islet transplantation. Two laparoscopic 
procedures were complicated by intra-abdominal bleeding when heparin injection was administered (2/3). 
Both cases received a blood transfusion without need for re-intervention. No portal vein thrombosis or 
puncture of the gallbladder occurred in either of the 2 approaches. 
 
Thirty-one cases of IS-related SAE were reported in 19 patients. Four patients presented 2 or more SAE. 
Two patients exhibited signs of Tac-related toxicity: 1 with encephalopathy and 1 with nephrotoxicity 
confirmed by renal biopsy, both resolving after dose reduction. The most frequently reported SAE caused 
by infection was posttransplantation CMV infection, observed in 5 patients (10%) and successfully treated 
with antiviral medication and/or reduction of MMF.  Four out of these 5 patients were CMV antibody 
negative before transplantation. The other CMV positive patient had reactivation of CMV at PT month 4. 
Four out of 5 patients developed CMV infection after prophylaxis was stopped.  One recipient with de novo 
CMV infection needed an additional course of oral valganciclovir because of persisting CMV PCR titers 
after IV ganciclovir. Gastro-intestinal infections, possibly related to the intake of IS, were the most common 
cause of hospitalization, resolving with either antibiotics or supportive therapy. 
 
There were 4 cancers reported; 1 metastasized gastric adenocarcinoma at age 56 with a fatal outcome at PT 
month 45, 1 acral lentiginous malignant melanoma at age 43 with complete remission after excision and 
cessation of MMF-Tac; 1 invasive prostate carcinoma at age 61 with complete resolution after total 
prostatectomy; and 1 invasive recto-sigmoid adenocarcinoma at age 47 with remission after laparoscopic 
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sigmoidectomy and cessation of MMF. Basocellular or squamous cell skin cancers or other nonskin cancers 
were not observed.  
 
Side effects are most prominent during the first 12 months PT 
During the first 12 months when the immune suppression dose was the highest, half of the patients 
experienced side effects but significantly decreased to 25% thereafter (Table 3). 
 
The most prominent symptoms observed the first year were gastrointestinal symptoms, mostly pyrosis, 
nausea and vomiting, which significantly decreased from the second year after transplantation (Table 4).  
Neurological symptoms, mostly memory impairment and headache were observed in 22% of the patients the 
first year, but significantly decreased at the second year and remained present in around 5% of the patients. 
Respiratory, musculo-skeletal symptoms, as well as asthenia and skin symptoms were prominent during the 
first year, but also showed a decreasing trend from the second year until 48 months.  
 
Laboratory abnormalities are most common during the first 6 months 
Abnormal liver function tests were observed during the first month PT, with increases in aspartate 
transaminase (AST > 2.5 times upper limit of normal) in 27% of all patients from median day 6, quickly 
resolving at day 9 and alanine aminotransferase (ALT > 2.5 times upper limit of normal) in 43% from day 6, 
resolving at day 12. These abnormalities were not seen after the second islet infusion (p<0.001 versus after 
first implant). 
 
All patients developed a decrease in blood cell counts (Table 3), consisting of lymphocytopenia (100%), 
anemia (67%) and thrombocytopenia (8%) in the first weeks after first implantation. Blood cell counts 
normalized thereafter, except for lymphocytopenia, which remained present in a third of the recipients under 
immune suppression until month 48 PT (Figure 2). Twenty-five percent of the patients received transfusion 
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for anemia, but no erythropoietin treatment was required. One patient required therapy with granulocyte 
colony-stimulating factor (G-CSF). No platelet transfusions were given.  
 
Implant function with metabolic control is sustained in 29 graft recipients  
Maximal basal C-peptide levels were reached at 3-6 months PT in both the group who continued IS for 48 
month (A; n=29) and those who stopped IS (B; n=16) during follow-up due to graft failure (Figure 3). In 
this period, C-peptide levels were twice as high in Group A than B, although after the first implantation 
(before month 3), a similar degree of beta cell implant function was measured in both groups. The insulin 
dose per kilogram in group A was reduced to half the dosage at this time, reaching nearly a third of the dose 
per kg of those in group B at 12 months (p=0.002) (Table 5). After month 12 PT, median C-peptide levels 
decreased at a similar pace in both groups. 
 
A striking inverse relationship was observed between implant function and both glycemic variability and 
insulin dose-adjusted A1c levels.  None of the patient experienced ketoacidosis or severe hypoglycemic 
events during the entire duration of the study while this was the case for 6 (group A) and 20 (group B) 
patients in the year preceding the transplantation. 
 
Tac trough levels as well as MMF dose were decreased with time, as defined in our protocol and there was 
no significant difference between group A and B observed (Table 5). 
 
Discussion  
This study shows that clinical benefits of islet transplantation outweigh the adverse events of chronic 
immune suppression in a large group of nonuremic type 1 diabetic patients. Patients with a functioning graft 
experience less glycemic variability with absence of severe hypoglycemia or episodes of ketoacidosis, 
without exposing them to unacceptable risks of chronic immune suppression. This positive risk-benefit ratio 
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is in line with the results of other groups (2,4,8,17-23) which studied more heterogeneous groups of islet-
alone and islet-after-kidney transplantation recipients and/or using different immune suppression regimens.  
Our patient group received cultured islet grafts (6) that were standardized in terms of beta cell number, 
purity and time frame of a second transplant. In order to achieve these objectives, islet beta cells from more 
than 1 donor were combined in each implant. Immunosuppression consisted of ATG induction and MMF-
Tac maintenance therapy, which is currently the most frequently used worldwide (9). 
 
Out of the 51 islet recipients, more than half of the patients experienced at least 1 side effect during the 48-
month follow-up. Both implantation procedures (laparoscopy(11) and transcutaneous(12)) were rarely 
associated with acute complications so that a negative impact on long-term islet function (24) was not seen 
in our cohort. Adverse events related to immune suppression were reported in 57% of patients. They 
occurred predominantly during the first year after transplantation, when the patients were treated with higher 
doses of MMF-Tac, together with the cumulative effect of ATG induction therapy and concomitant 
prophylactic medication. As observed in other transplant protocols (25-29), gastro-intestinal and 
neurological symptoms, well-recognized side effects of respectively MMF and/or Tac, were the most 
frequent in this study. MMF-related gastrointestinal symptoms rarely needed hospitalization and resolved 
after short-term supportive therapy. The majority of these AE resolved after dose reduction of immune 
therapy and side effects of grade 2 or more were observed in only a quarter of patients after the first year. In 
line with other reports (30-32), the majority of patients in the present study found the side effects less 
debilitating when compared to severe hypoglycemic episodes and unstable metabolic control and were 
satisfied with the transplantation. 
 
In all patients, depletion of blood cells was observed in the first month after the first implant, caused by 
ATG induction, start of maintenance immune suppression and the administration of valganciclovir and 
trimethoprim-sulfamethoxazole. Frequent blood sampling in the peritransplant period may have aggravated 
anemia. Most patients presented with neutropenia during the first month, but this was not associated with 
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serious infections or high numbers of opportunistic infections. All patients had prolonged lymphocytopenia. 
The use of lymphocyte-depleting therapies is a well-recognized risk factor for cytomegalovirus infection 
(33-35), explaining the comparable CMV disease incidence in our cohort as in the study of Gala-Lopez et al 
(35) (9% vs 9.5%). It is also in line with lower CMV disease incidence observed in other islet transplant 
cohorts not using T-cell depletion (4,36). An additional important risk factor for CMV disease is the use of 
sero-positive organ donors in sero-negative recipients (37-39), which was the case in 4 out of 5 patients in 
our study. Except for 1 patient, CMV disease occurred more than 100 days after the transplantation, when 
prophylactic valganciclovir was stopped according to our protocol. Extending the duration of prophylactic 
therapy might prevent additional cases as shown after kidney transplantation (40). 
 
Cancer is a well-established risk of chronic immune suppression (41). None of the patients in our cohort 
developed lymphoma or related diseases. Four patients with a well-functioning islet graft were diagnosed 
with cancer, 3 of them after year 2 PT.  In 3 patients, diagnosis was made at an early stage, with immediate 
reduction (prostate cancer, colon cancer) or cessation (melanoma) of IS and follow-up has been so far 
uneventful. One patient died from liver metastasized gastric carcinoma. Although we cannot rule out the 
contribution of IS in the occurrence of this late stage gastric cancer, it is probable that an underlying 
pathology was already present before transplantation. This is probably also the case for the 3 SAE due to 
macrovascular events since they occurred in the early stages after transplantation (1, 4 and 18 months PT) in 
a patient population with already a high incidence of pre-existing macrovascular disease. Nevertheless, our 
findings emphasize the need for frequent monitoring of islet transplant recipients. 
 
Another well-known risk of calcineurin-inhibitor based immune suppression is deterioration of native 
kidney function in recipients of a nonrenal organ (42). In a previous study, we already showed that the use 
of Tac caused an initial 20% reduction in eGFR, which was reversible following its discontinuation (43). 
Moreover, the risk-benefit ratio of IS regimen using sirolimus with lower levels of Tac is not better than IS 
regimens using MMF with higher levels of Tac (44). Our previous study using sirolimus-Tac or sirolimus 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
  
alone showed in patients with preexisting microalbuminuria, a worsening of albuminuria that was caused by 
sirolimus (45), supporting further use of a MMF-Tac based regimen in this patient population (43). 
 
The most relevant clinical benefit for the patients was the absence of severe hypoglycemia 
posttransplantation. All patients also had significantly better (insulin dose-adjusted) HbA1c and a significant 
reduction in glycemic variability, which are well-known risk factors both for long-term complications and 
hypoglycemia (46-49).  While C-peptide levels were comparable to patients with optimal graft function in 
other studies (2,7,9), maintenance of insulin independence was similar (2) or  lower  in our cohort. While 
this can be a sign of more rapid decline in beta-cell mass, our approach has always been to rapidly restart 
insulin if glucose values become abnormal pre- or postprandial, leading to early reintroduction of insulin. 
 
The patient group where immune suppression was stopped because of loss of graft function had similar 
initial graft function (ie 0-3 months) as the group that maintained graft function during 48 months. The last 
group exhibited a 2-fold rise in graft function during the 3-6 months PT while no increase in graft function 
was measured in the patient group that failed within the first 4 years. This is in line with the publication by 
Vantyghem et al (7), emphasizing the importance of optimal graft function 1 month after the last implant in 
maintaining long-term graft function with the Edmonton protocol. 
 
The patient group who became C-peptide negative during follow-up was significantly younger. There are no 
surrogate markers that allow us to examine the possible reasons for this difference in outcome.  MMF and 
Tac levels were not different with the first year PT but the patients with less favorable outcome were 
significantly younger and had a significantly worse baseline glucose control. Because HbA1c was not 
different at 0-3 months PT, we hypothesize that immune-related factors rather than metabolic factors are 
responsible for the worse outcome.  It is well established in other organ transplantation settings that older 
age is associated with improved transplant survival and lower rates of rejection (50). Another reason for 
worse graft function in younger patients might be less compliance with the immunosuppressive regimen 
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(51,52). Future islet transplant protocols can explore the risk-benefit ratio of more potent immune 
suppressive regimen, especially in younger subjects. 
 
In our cohort under immune suppression during 48 months, a decline in implant function started already 
after the first year. It is unknown whether this decline is due to a reduction in Tac and/or MMF and/ or a 
limited graft beta cell mass that is vulnerable to metabolic stress. Studies are ongoing that aim to reduce the 
important loss of functional beta cells immediately after intraportal transplantation (53-56) 
(ClinicalTrials.gov Identifier:NCT00789308). A phase 1 study with embryonic stem cell derived endocrine 
cells (57) has also been started (ClinicalTrials.gov identifier: NCT02239354); this new cell source may 
overcome the barrier of the limited amount of cells that is available for transplantation when deceased 
donors are used. 
 
In conclusion, islet transplantation using ATG in combination with MMF-Tac is safe to use long-term, with 
side effects mostly limited to the first year with the maintenance of metabolic benefit in those with good 
initial graft function.  
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Figure Legends 
 
Figure 1: Flow chart of number of patients on immune suppression therapy following beta cell 
transplantation. 
 
Figure 2:  Depletion of blood cells in nonuremic type 1 diabetic recipients of long-term cultured islet 
beta cell allograft under immune suppression. Pre-Tx: pre-transplantation, IS: Immune suppression 
 
Figure 3: Implant function and metabolic control in diabetic recipients of long-term cultured islet 
beta cell allograft. Data are shown as mean ± SEM. Random C-peptide measured when glycaemia between 
120-220 mg/dl. Group A: Under immune suppression for 48 months, Group B: immune suppression stopped 
before 48 months due to graft failure. IS: immune suppression, CVfg: coefficient of variation of fasting 
glycemia, IDAA1c: Insulin dose-adjusted hemoglobin A1c. Statistically significant compared with Group B 
*p<0.05, 
$
p<0.005. 
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Table 1: Patient and Graft characteristics 
Immune Therapy 48 months Stop during 48 months 
  Graft Failure Other reasons 
n 29 16 6 
General    
     Male/Female 17/12 9/7 3/3 
     Body weight (kg) 66 (63-70) 70  (67-77) 69 (63-76) 
     BMI (kg/m²) 23 (22-25) 24 (22-26) 25 (23-28) 
     Age at first islet transplantation (years) 46 (40-54) 37 (32-43)$ 50 (44-55) 
Diabetes    
     Age at clinical onset (years) 15 (12-26) 11 (8-22) 30 (14-37) 
     Duration of disease (years) 28 (24-38) 23 (20-29) 17 (12-42) 
     Positivity for ICA/GADA/IA2A/I(A)A 5/13/7/26 3/3/6/14 0/2/2/6 
          ≥ 1 Auto-antibody positivity (%) 97 94 100 
          Auto-antibody negative (%) 3 6 0 
     HbA1c (%) 7.5 (6.9-8.2) 8.1 (7.4-8.8) 7.8 (7.3-8.3) 
     Insulin dose (IU/day) 34 (28-42) 42 (32-58) 39 (32-54) 
     Insulin dose (IU/kg/day) 0.55 (0.42-0.63) 0.58 (0.52-0.79) 0.56 (0.49-0.72) 
     IDAA1c (%) 9.4 (9.0-10.4) 10.6 (9.5-11.3)* 10.1 (9.4-10.8) 
     CV fasting glycemia (%) 46 (40-50) 47 (41-55) 49 (37-54) 
     Microvascular complications    
        Diabetic retinopathy  (yes) 25 12 3 
        Microalbuminuria  (yes) 4 4 3 
     Macrovascular complication# 14 4 2 
Graft    
     Culture time (days) 5 (3-10) 5 (3-10) 4 (2-7) 
     Number of islet infusions 2 2 2 
     Beta cell number (106/kg body weight) 2.6 (2.3-3.1) 2.7 (2.0-3.3) 2.6 (2.3-3.4) 
     Cellular composition (%)    
          Beta cells 29 (22-37) 26 (20-35) 24 (24-33) 
          Alpha cells 8 (5-11) 7 (5-13) 9 (6-14) 
          Non-granulated cells 49 (41-61) 52 (41-59) 46 (39-49) 
          Acinar cells 1 (1-6) 2 (1-5) 3 (1-6) 
          Dead cells 8 (6-11) 9 (7-11) 8 (7-12) 
Data are shown as median (IQR). 
IDAA1c: Insulin dose-adjusted A1c 
CV fasting glycemia defined by 100 X (standard deviation/mean) 
#
Macrovascular complication is defined as a combined endpoint (carotid stenosis, coronary heart disease, and arterial stenosis of 
the lower limbs 
Statistical difference between IS continue group versus graft failure group or stopped due to other reasons group (Mann-Whitney 
U) *p < 0.05,  
$
p< 0.005 
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Table 2. Number and type of Severe Adverse Events  (SAE) 
Number of patients with SAE (%) 
Number of 
SAE (%) 
Relationship 
to study 
Description Post-Transplantation Treatment Outcome 
Total 24 (47) 37 (100)  
    
Procedure-related 
 
3 (6) 3 (8) Definitely 
-Abdominal bleeding post-laparoscopy 
-Diaphragm irritation post-
percutaneous puncture 
Day 1, day 1 
 
Day 5 
Transfusion (1) 
 
Resolution 
Immune suppression-
related 
19 (37) 31 (84) 
Definitely 
- Tacrolimus encephalopathy 
- Tacrolimus nephropathy 
Mo 26 
Mo 30 
Stop tacrolimus  
Dose reduction 
Resolution 
Probably 
CMV infection Mo 1, 17 
Mo 4 
Mo 6 
 
Mo 23 
IV ganciclovir 
PO valganciclovir, MMF reduction 
IV ganciclovir, PO valganciclovir, 
MMF reduction 
Stop MMF 
Resolution 
Anemia Mo 0, 1, 4, 15 Transfusion Resolution 
Opportunistic infection 
- Candida oesophagitis 
- Microsporidium 
 
Mo 5 
Mo 10 
 
Fluconazole  
Albendazole and MMF stop 
Resolution 
Leucopenia of unknown origin Mo 9 MMF dose reduction Resolution 
Possibly 
Gastro-intestinal 
- Gastro-enteritis 
- Left fossa pain  
- Chronic diarrhea  
 
Mo 0, 1, 1, 3, 6, 9, 10, 17, 19 
Mo 2 
Mo 39 
 
Antibiotics (2) 
 
Antibiotics and stop MMF 
Resolution 
Other viral infections Mo 23, 25  Resolution 
Diffuse liver metastasis of gastric 
adenocarcinoma 
Mo 27 Chemotherapy Death 
Acral lentiginous melanoma Mo 13 Resection, stop immune suppression Resolution 
Invasive prostate adenocarcinoma Mo 24 Total prostatectomy Resolution 
Invasive sigmoid adenocarcinoma Mo 34 Resection, stop MMF Resolution 
Other 2 (4) 3 (8) Probably not 
Instable angina Mo 1 CABG Resolution 
Cerebral hemorrhage Mo 4 Drainage Death 
Exercise-induced angina Mo 18 PTCA Resolution 
 
No specific therapy is mentioned when symptoms resolved with conservative management 
SAE: serious adverse events, Mo: months, MMF: mycophenolate mofetil, CABG: coronary artery bypass graft, PTCA: percutaneous transluminal coronary angioplasty 
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Table 3. Percent (%) of patients experiencing at least one adverse event under immune suppression therapy during 48 months follow up 
 Total 48 months follow-up  
Month 
0-12 12-24 24-36 36-48 
Number of patients under IS 51  51 38 34 29 
Serious Adverse Events 47%  33%  18% 15% * 3% * 
Side effects 
(signs and symptoms) 
57%  51% 26% * 21% * 21% * 
Depletion of blood cells♯ 100%  100% 66% $ 47% $ 31% $ 
♯
 Neutropenia and/or lymphocytopenia and/or anemia and/or thrombocytopenia  
Statistically significant reduction of adverse events compared with first year PT (PT month 0-12), *p<0.05, 
$
p <0.001 
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Table 4. Prevalence of side effects€ in non-uremic Type 1 diabetic recipients of long-term cultured islet beta cell allograft under immune suppression 
Follow-up Patients 
Side effects 
n (%) 
PT months n Gastrointestinal Neurological Respiratory Musculoskeletal Asthenia Skin 
0-1 51 11 (22) 5 (10) 3 (6) 4 (8) 3 (6) 0(0) 
1-12 51 15 (29) 11 (22) 8 (16) 7 (14) 6 (12) 6 (12) 
12-24 38 4 (11)* 1 (3)* 2 (5) 4 (11) 3 (8) 3 (8) 
24-36 34 3 (9)* 2 (6) 3 (9) 3 (9) 1 (3) 2 (6) 
36-48 29 1 (3)* 2 (7) 2 (7) 3 (10) 1 (3) 2 (7) 
 
€ Grade ≥ 2 symptoms in > 5 percent of patients 
PT: post-transplantation 
Statistically significant reduction of patients experiencing side effects compared with first year posttransplantation (PT month 0-12), *p<0.05 
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Table 5. Implant function and metabolic control in diabetic recipients of long-term cultured islet beta cell allograft 
 
 
  
Immune suppression Metabolic control 
Follow-
up 
Patient 
number 
n 
Tacrolimus trough  
 
(ng/ml) 
MMF dose$ 
 
(mg/day) 
C-peptide
#
 
 
(ng/ml) 
CVfg 
 
(%) 
HbA1c 
 
(%) 
Insulin dose 
 
(IU/kg/day) 
% of patients with 
Insulin independence  
% patients with 
detectable c-peptide 
(≥0.2 ng/ml) 
PT months A B A B A B A B A B A B A B A B A B 
Before Tx 29 16     
0.09 
(0.09-0.09) 
0.09 
(0.09-0.09) 
46 
(40-50) 
47  
(41-55) 
7.6 
(7.0-8.3) 
8.1 
(7.5-8.8) 
0.55  
(0.42-0.63) 
0.58  
(0.52-0.79) 
    
0 - 3 29 16 
9.5 
(8.8-10.2) 
10.0 
(9.0-10.2) 
2000 
(2000-2000) 
2000 
(2000-2000) 
0.81 
(0.45-1.21) 
0.77 
(0.48-1.22) 
26 
(0-36) 
26 
 (20-31) 
5.4 
(5.0-6.2) 
5.7 
(5.1-5.9) 
0.39  
(0.30-0.52) 
0.41 
 (0.22-0.56) 
3 6 97 94 
3- 6 29 16 
8.9 
(8.0-10.0) 
9.2 
(8.0-10.5) 
1500 
(1000-2000) 
1500 
(1500-2000) 
2.06$ 
(1.46-2.50) 
1.00 
(0.67-1.60) 
16* 
(12-22) 
25 
 (17-34) 
6.0 
(5.5-6.2) 
6.1 
(5.6-7.0) 
0.16  
(0.02-0.29) 
0.27  
(0.20-0.48) 
48 19 100 100 
6- 12 29 15 
8.7 
(8.0-9.1) 
7.3 
(6.5-10.0) 
1500 
(1000-1500) 
1500 
(1500-2000) 
1.85$ 
(1.07-2.74) 
0.53 
(0.28-0.97) 
16$ 
(11-20) 
36  
(23-46) 
6.4* 
(5.9-6.8) 
6.7  
(6.2-7.5) 
0.13 $ 
(0-0.25) 
0.33  
(0.20-0.48) 
52 13 100 93 
12-24 29 8 
8.0* 
(6.9-8.0) 
6.5 
(4.4-7.6) 
1250 
(1000-1500) 
1500 
(1250-1500) 
1.39* 
(0.52-1.93) 
0.45 
(0.21-1.22) 
22 
(18-28) 
31 
 (18-42) 
6.7 
(6.3-7.1) 
7.2  
(6.4-7.7) 
0.20  
(0.09-0.30) 
0.36 
 (0.07-0.45) 
38 14 100 88 
24-36 29 5 
7.0 
(6.3-8.0) 
6.5 
(2.2-8.6) 
1000 
(1000-1500) 
1250 
(1000-1250) 
0.80 
(0.52-1.34) 
0.19 
(0.10-0.95) 
26 
(23-33) 
34 
 (30-35) 
7.0 
(6.5-7.5) 
7.1  
(5.8-7.7) 
0.29  
(0.17-0.39) 
0.43  
(0.19-0.53) 
14 0 97 40 
36- 48 29 0 
7.0 
(5.0-8.4) 
 
1000 
(1000-1500) 
 
0.66 
(0.31-1.01) 
 
33 
(25-36) 
 
7.2 
(6.2-8.0) 
 
0.31  
(0.23-0.42) 
 7  93  
 
Data are shown as median (IQR) 
PT: posttransplantation, IS: immune suppression, MMF: mycophenolate mofetil 
A: Under immune suppression for 48 months, B: immune suppression stopped before 48 months due to graft failure 
$
 Total 4 patients  (3 in IS continue and 1 in IS stop group) were temporarily under mycophenolic acid (Myfortic®) during the first year and switched to mycophenolate 
mofetil (Cellcept®) thereafter. 
#
 Median C-peptide with glycemia between 120-220 mg/dl 
Statistically significant compared with Group B *p<0.05, 
$
p<0.005 
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